HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 ...

SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...